NO920051L - Farmasoeytisk sammensetning for slanking - Google Patents

Farmasoeytisk sammensetning for slanking

Info

Publication number
NO920051L
NO920051L NO92920051A NO920051A NO920051L NO 920051 L NO920051 L NO 920051L NO 92920051 A NO92920051 A NO 92920051A NO 920051 A NO920051 A NO 920051A NO 920051 L NO920051 L NO 920051L
Authority
NO
Norway
Prior art keywords
ephedrine
caffeine
pharmaceutical composition
composition
slimming
Prior art date
Application number
NO92920051A
Other languages
English (en)
Norwegian (no)
Other versions
NO920051D0 (no
Inventor
Arne Astrup
Original Assignee
Dak Lab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dak Lab As filed Critical Dak Lab As
Publication of NO920051D0 publication Critical patent/NO920051D0/no
Publication of NO920051L publication Critical patent/NO920051L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO92920051A 1989-07-07 1992-01-03 Farmasoeytisk sammensetning for slanking NO920051L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK339289A DK339289D0 (da) 1989-07-07 1989-07-07 Farmaceutisk praeparat
PCT/DK1990/000106 WO1991000730A1 (en) 1989-07-07 1990-04-20 A slimming pharmaceutical composition

Publications (2)

Publication Number Publication Date
NO920051D0 NO920051D0 (no) 1992-01-03
NO920051L true NO920051L (no) 1992-01-31

Family

ID=8122369

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92920051A NO920051L (no) 1989-07-07 1992-01-03 Farmasoeytisk sammensetning for slanking

Country Status (18)

Country Link
US (1) US5422352A (de)
EP (1) EP0480934B1 (de)
JP (1) JP2584899B2 (de)
KR (1) KR0159045B1 (de)
AT (1) ATE107858T1 (de)
AU (1) AU638992B2 (de)
CA (1) CA2063598C (de)
DE (1) DE69010336T2 (de)
DK (2) DK339289D0 (de)
ES (1) ES2055911T3 (de)
FI (1) FI920026A7 (de)
HU (1) HU220071B (de)
LT (1) LT3536B (de)
LV (1) LV10192B (de)
NO (1) NO920051L (de)
RU (1) RU2109511C1 (de)
UA (1) UA27779C2 (de)
WO (1) WO1991000730A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5865869A (en) * 1991-08-02 1999-02-02 Ecologel Usa, Inc. Solution for plant root watering
WO1994000432A1 (en) * 1992-06-30 1994-01-06 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Anorectic epinephrine derivatives
EP0671936A1 (de) * 1992-10-15 1995-09-20 Dana-Farber Cancer Institute, Inc. Behandlung der insulinresistenz bei mit übergewicht verbundenem type ii-diabetes mittels antogonisten gegen die funktion von tnf-g(a)
ES2094687B1 (es) * 1994-08-02 1997-12-16 S A L V A T Lab Sa Combinacion farmaceutica contra la obesidad o el sobrepeso.
FR2746644A1 (fr) * 1996-03-18 1997-10-03 Firion Jackie Produit parapharmaceutique moderateur d'appetit
US6224873B1 (en) 1996-09-30 2001-05-01 Zhishin, Llc Regulation of appetite, body weight and athletic function with materials derived from citrus varieties
ES2339908T3 (es) * 1996-09-30 2010-05-26 Dennis Jones Regulacion del peso corporal con materiales derivados de variedades del genero de citricos.
DK0946155T4 (da) 1996-12-23 2009-05-11 Sla Pharma Ag Farmaceutisk sammensætning til behandling af fækal inkontinens
US6162455A (en) * 1997-01-22 2000-12-19 American Cyanamid Company Method for increasing lean meat, improving the lean meat to fat ratio and improving amino acid utilization in warm-blooded animals
US5985282A (en) * 1997-01-22 1999-11-16 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
US5798101A (en) * 1997-01-22 1998-08-25 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
HUP9700654A2 (hu) 1997-03-26 1999-09-28 Dezső Korbonits Teobromin tartalmú köhögéscsillapító készítmények
US6468519B1 (en) * 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
NZ509198A (en) 1998-06-26 2002-11-26 Elaine A Treatment for multiple sclerosis using a histamine H2 agonist in combination with a phosphodiesterase inhibitor
US7232830B2 (en) 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
US6340482B1 (en) * 2000-05-18 2002-01-22 Zhishin, Llc Methods for inducing weight loss in a human with materials derived from Citrus varieties
US6113949A (en) * 1998-10-27 2000-09-05 Prolab Nutrition, Inc. Weight control product and method of treating hyperlipidemia and increasing vigor with said product
US6475514B1 (en) * 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
FR2788438B1 (fr) * 1999-01-14 2003-10-03 Arkopharma Laboratoires Composition pour le traitement de l'obesite et procede de traitement esthetique
US6576272B1 (en) * 1999-03-05 2003-06-10 Twin Laboratories Incorporated Dietary supplement and method of using same
AU6221500A (en) * 1999-07-20 2001-02-05 Natrol, Inc. Weight control product comprising a synergistic mixture of guggul extract, phosphate salt and metabolic stimulant
MXPA02001882A (es) * 1999-08-23 2002-08-20 Univ Tulane Modulacion del transportador de leptina a traves de la barrera hemato-encefalica.
US6723737B1 (en) * 1999-10-20 2004-04-20 Eliezer Rapaport Methods, pharmaceutical and therapeutic compostions for administering adenosine
US7115297B2 (en) * 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
US8178150B2 (en) 2000-02-22 2012-05-15 Suzanne Jaffe Stillman Water containing soluble fiber
US7892586B2 (en) 2001-02-22 2011-02-22 Suzanne Jaffe Stillman Water containing soluble fiber
DE10011541A1 (de) * 2000-03-06 2001-09-20 Reimann Hartmut Verwendung einer Kombination aus Ephedrin und Coffein und/oder Theophyllin zur Vitalisierung von Knochenfischen, Wasserzusatz zur Vitalisierung von Knochenfischen
US6316499B1 (en) 2000-05-18 2001-11-13 Zhishin, Llc Methods for increasing the muscle mass of a human with materials derived from citrus varieties
KR20030005204A (ko) * 2000-12-25 2003-01-17 가부시키가이샤 시세이도 교감신경 활성화 향료 조성물
US7048941B2 (en) * 2001-03-30 2006-05-23 New World Enterprizes, Inc. Chocolate composition as delivery system for nutrients and medications
WO2003022239A2 (en) * 2001-09-07 2003-03-20 Western Holdings Llc Stable water in oil aminophylline emulsions
RU2209582C2 (ru) * 2001-10-22 2003-08-10 Горелик Самуил Лейбович Способ контроля веса пациента
GB0130763D0 (en) 2001-12-21 2002-02-06 Norgine Res Ltd Treatment methods
WO2003088953A2 (en) * 2002-04-19 2003-10-30 N.V. Nutricia Multiphasic diet
US8142810B2 (en) * 2002-05-30 2012-03-27 The Procter & Gamble Company Dietary method for modulating glucose metabolism and associated conditions and increasing longevity
US20040077530A1 (en) * 2002-10-18 2004-04-22 Robert Portman Composition for reducing caloric intake
US20040224031A1 (en) * 2003-05-06 2004-11-11 Antonio Zorzano Olarte Combination of amines and vanadium (IV)/(V) compounds for the treatment and/or prevention of diabetes mellitus
CA2559836C (en) 2003-10-17 2014-08-12 Diet Formulations Ltd. Thermogenic and fiber containing weight-loss supplement
WO2005051092A2 (en) * 2003-11-20 2005-06-09 Alteragon Pty Ltd Method of decreasing fat deposits and body weight in mammals and birds
PL209905B1 (pl) * 2004-01-15 2011-11-30 Bringwell Internat Ab Preparat do leczenia otyłości i związanego z nią syndromu metabolicznego
CA2455248A1 (en) * 2004-01-29 2005-07-29 Alexander Zolotoy Oral administration of r-albuterol against obesity
US7524064B2 (en) * 2004-03-09 2009-04-28 Research Foundation Of The State University Of New York Apparatus and method for assessing retinal damage
US20060074057A1 (en) * 2004-10-04 2006-04-06 Eric Marchewitz Use of chenodeoxycholic acid for reducing adipose tissue
US20060134230A1 (en) * 2004-12-17 2006-06-22 Sal Abraham Weight loss composition and formulation
US20060204599A1 (en) * 2005-03-14 2006-09-14 Wheat Jared R Dietary supplement and method of using same
US20090214682A1 (en) * 2008-02-22 2009-08-27 Heuer Marvin A Composition and methods for weight loss in a subject
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US9610429B2 (en) * 2010-12-29 2017-04-04 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue with targeted substance delivery
US9271982B2 (en) 2012-10-08 2016-03-01 Rivalea (Australia) Pty Ltd. Animal feed supplement comprising ractopamine and caffeine
US9877434B2 (en) 2013-05-30 2018-01-30 Ecologel Solutions, Llc Granular compositions and methods for drought mitigation
AU2015234690B2 (en) * 2014-03-26 2019-08-29 Rivalea (Australia) Pty Ltd Method for improving feed efficiency in ruminants
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
CN120436205A (zh) 2015-02-13 2025-08-08 马斯公司 包装宠物食物产品
WO2016167855A1 (en) * 2015-04-14 2016-10-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Combination of albuterol and caffeine as synergistic treatment for obesity or sarcopenia
GB201522296D0 (en) 2015-12-17 2016-02-03 Mars Inc Food product to reduce body fat
US11090278B2 (en) 2019-05-16 2021-08-17 Nexus Pharmaceuticals, Inc. Compositions comprising ephedrine or an ephedrine salt and methods of making and using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2390164A1 (fr) * 1977-05-13 1978-12-08 Blanie Paul Association a action anti-asthmatique
DE2743702A1 (de) 1977-06-03 1978-12-14 Pharmaceutical Export Promotio Abmagerungs- oder schlankmacher- zubereitung und verfahren zu ihrer herstellung
US4364922A (en) * 1980-10-14 1982-12-21 University Of Virginia Alumni Patents Foundation Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US5011843A (en) * 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors

Also Published As

Publication number Publication date
DK0480934T3 (da) 1994-11-07
WO1991000730A1 (en) 1991-01-24
CA2063598C (en) 1997-12-09
LV10192A (lv) 1994-10-20
DK339289D0 (da) 1989-07-07
HK1001821A1 (en) 1998-07-10
ATE107858T1 (de) 1994-07-15
LT3536B (en) 1995-11-27
DE69010336T2 (de) 1994-11-03
HU9200051D0 (en) 1992-06-29
NO920051D0 (no) 1992-01-03
HUT62798A (en) 1993-06-28
HU220071B (hu) 2001-10-28
FI920026A0 (fi) 1992-01-03
ES2055911T3 (es) 1994-09-01
JPH04507091A (ja) 1992-12-10
AU5630890A (en) 1991-02-06
LTIP702A (en) 1995-01-31
CA2063598A1 (en) 1991-01-08
FI920026A7 (fi) 1992-01-03
JP2584899B2 (ja) 1997-02-26
RU2109511C1 (ru) 1998-04-27
EP0480934A1 (de) 1992-04-22
EP0480934B1 (de) 1994-06-29
KR0159045B1 (ko) 1998-12-01
AU638992B2 (en) 1993-07-15
UA27779C2 (uk) 2000-10-16
LV10192B (en) 1995-06-20
DE69010336D1 (de) 1994-08-04
US5422352A (en) 1995-06-06

Similar Documents

Publication Publication Date Title
NO920051L (no) Farmasoeytisk sammensetning for slanking
DE59207852D1 (de) Peroral applizierbare arzneiform zur behandlung zentraler dopaminmangelzustände
MD1450F2 (en) Aspartam derivatives or physiologic acceptable salts thereof, process of preparation and sweetening composition
KR880012217A (ko) 캘콘 유도체를 사용한 종량 조직의 증식 억제방법
DK630287A (da) Farmaceutisk praeparat med reguleret afgivelse
KR960003729A (ko) 항과혈당증 작용을 지닌 약제
GB8523338D0 (en) Treatment of obesity
Smith et al. Adrenal enlargement and its significance in the hognose snakes (Heterodon)
KR880005928A (ko) 에브셀렌(Ebselen)의 새로운 의약적 용도
Taylor et al. Antidiuretic substance in human urine after smoking
KR890003373A (ko) 수면장애 및 우울증 치료에 화합물의 이용
KR880004810A (ko) 소화성 궤양 치료제
REVENO et al. Treatment of hyperthyroidism with 1-methyl-2-mercaptoimidazole
Schmidt et al. Early increased pancreatic secretory capacity during alcohol adaptation in the dog
Mooney The flushing patient.
Chrysant et al. The effects of salt and meclofenamate administration on the hypertension of spontaneously hypertensive rats
KR900017599A (ko) 종양 치료용 약학 조성물
Schmidt et al. Effect of a calcium chelator on morphine tolerance development
Gregory Elements of the Practice of Physic
Swartz Dependency of tricyclic antidepressant efficacy on thyroid hormone potentiation: Case studies
KR890012651A (ko) 이뇨제 또는 항고혈압제 조성물
Shechtman et al. Sex differences in vascular reactivity to adrenergic agents in the rat
JP4792702B2 (ja) 肥満の予防または改善用組成物
Neufeld et al. Further studies on the antagonist to adrenalin hyperglycemia in pituitary extracts
KR890014115A (ko) 4-(3-포스포노-2-프로페닐)-2-피페라진카르복실산의 신규한 용도